Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead bifunctional antibody, ficerafusp alfa, for solid tumors. Company announcements frequently highlight progress in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative disease, and provide updates on related clinical trials and regulatory interactions.
Recent news has included updates on the pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa in combination with pembrolizumab in first-line HPV-negative R/M HNSCC, preliminary and expanded Phase 1/1b cohort data, and the selection of dosing strategies intended to inform the pivotal study. Bicara has also reported that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in a defined subset of R/M HNSCC patients, and has used press releases to discuss how clinical data supported this designation.
In addition to clinical milestones, BCAX news items cover quarterly financial results, research and development spending, and cash and investment balances, reflecting the company’s status as a clinical-stage public issuer. Bicara also issues releases about participation in major medical and investor conferences, such as oncology congresses and healthcare investment events, where it presents clinical data or engages with the investment community.
Investors and observers following BCAX news can expect updates on FORTIFI-HN01 enrollment and interim analyses, data readouts from Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer, regulatory designations and guidance, and broader corporate developments. This news page aggregates those disclosures to help readers track the evolving clinical and corporate narrative around ficerafusp alfa and Bicara’s broader solid tumor strategy.
Bicara Therapeutics (Nasdaq: BCAX) will report first quarter 2026 financial results and business updates before the market opens on May 11, 2026. A conference call will follow at 8:30 a.m. ET, with a live webcast and a replay available for 30 days.
Registration is required for dial-in details and a unique PIN; the webcast is available in the Investors & Events section on the company website.
Bicara Therapeutics (Nasdaq: BCAX) awarded an inducement non-qualified stock option on April 1, 2026, to a new employee for 44,175 shares at an exercise price of $20.50, equal to the Nasdaq closing price on April 1, 2026.
The option vests 25% after one year, then in 12 equal quarterly installments, and was granted under Bicara’s 2026 Inducement Plan adopted in January 2026 and approved by an independent compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) reported Q4 and full-year 2025 results and business updates on March 30, 2026. The company selected 1500mg ficerafusp alfa for Phase 3 FORTIFI-HN01, initiated Phase 3, and expects an interim analysis mid-2027. Bicara announced a less‑frequent loading/Q3W maintenance schedule and reported a cash position of $414.8M as of Dec 31, 2025, with an additional $161.8M raised in Q1 2026 to fund operations into H1 2029.
R&D and G&A expenses and net loss widened in 2025 versus 2024 amid pivotal trial investments.
Bicara Therapeutics (Nasdaq: BCAX) will report fourth quarter and full year 2025 financial results and provide business updates on March 30, 2026 before market open. A conference call and live webcast will occur at 8:30 a.m. ET, with registration, dial-in PINs, and a 30-day replay available.
Bicara Therapeutics (Nasdaq: BCAX) awarded an inducement non-qualified stock option on March 2, 2026 to a new employee for 115,000 shares at an exercise price of $17.59, equal to the Nasdaq closing price that day.
The award vests 25% after one year, then in 12 equal quarterly installments, was granted under Bicara’s 2026 Inducement Plan (adopted January 2026) and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) closed an oversubscribed underwritten public offering on Feb 26, 2026, selling 8,581,250 shares and offering pre-funded warrants for 2,200,000 shares.
The underwriters fully exercised a 1,406,250-share option. Public prices were $16.00 per share and $15.9999 per pre-funded warrant, generating approximately $172.5 million gross proceeds before fees. Bicara plans to use net proceeds for regulatory filing and potential U.S. commercial launch of ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.
Bicara Therapeutics (Nasdaq: BCAX) priced an underwritten public offering of 7,175,000 common shares at $16.00 per share and 2,200,000 pre-funded warrants at $15.9999 each, for gross proceeds of approximately $150 million. Closing is expected on or about February 26, 2026.
The company granted a 30-day underwriter option for 1,406,250 additional shares. Net proceeds will fund regulatory and commercial preparation for ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.
Bicara Therapeutics (Nasdaq: BCAX) commenced an underwritten public offering of $150.0 million of common stock on February 24, 2026, with a 30‑day underwriter option to purchase up to an additional $22.5 million.
Proceeds are intended to fund the U.S. regulatory filing and potential commercial launch of ficerafusp alfa, accelerate development in 1L R/M HPV‑negative HNSCC, cover manufacturing costs, support indication expansion work, and for general corporate purposes. The offering is subject to market conditions and will be made from an effective Form S‑3 shelf registration.
Bicara Therapeutics (Nasdaq: BCAX) said company leadership will attend multiple investor conferences in early March 2026, with live fireside chats and webcasts scheduled. Ryan Cohlhepp, Pharm.D., President and COO, will present at TD Cowen (Mar 2) and Barclays (Mar 10) and attend Jefferies Biotech on the Beach (Mar 10-11).
Live webcasts and archived replays will be available via the company’s Investor Relations Events and Presentations page.
Bicara Therapeutics (Nasdaq: BCAX) presented Phase 1b data showing 2000mg ficerafusp alfa Q2W plus pembrolizumab produced a 48% confirmed ORR, 26% CR rate and 77% of responders with ≥80% tumor shrinkage (n=27; data snapshot Dec 16, 2025).
Results show sustained TGF-β inhibition and support development of a loading plus every‑three‑week maintenance regimen; a conference call is scheduled for Feb 20, 2026 at 8:30 a.m. ET.